Latest news about Shree Ganesh Remedies
Shree Ganesh Remedies
650.00
+1.75(+0.27%)
Company Performance:
View Company Insights1D+0.27%
1M+24.84%
6M+35.95%
1Y+6.14%
5Y+132.72%
More news about Shree Ganesh Remedies
23Jan 26
Shree Ganesh Remedies Limited Announces Q3FY26 Financial Results
Shree Ganesh Remedies Limited announced Q3FY26 results showing revenue from operations of ₹2,110.68 lakhs and net profit of ₹309.62 lakhs on standalone basis, both declining compared to Q3FY25. For nine months, revenue was ₹7,608.96 lakhs with net profit of ₹1,150.11 lakhs. The company's earnings per share for the quarter was ₹2.41, down from ₹4.23 in the previous year.
16Jan 26
Shree Ganesh Remedies Reappoints Parth Kothia as Whole Time Director for Five Years
Shree Ganesh Remedies Limited's board approved the re-appointment of Mr. Parth Chandulal Kothia as Whole Time Director and CFO for five years from January 17, 2026. The Chemical Engineering graduate with an MS in Global Finance from Fordham University has over five years of experience in pharmaceutical business development and has been instrumental in driving company growth since 2021. His re-appointment, subject to shareholder approval, continues his dual role as director and CFO.
08Aug 25
Shree Ganesh Remedies Strengthens Board with New Independent Director and Reappoints Cost Auditor
Shree Ganesh Remedies Limited has appointed Ms. Shruti Sohane as an Additional Director (Non-Executive, Independent) for a five-year term, effective August 08, 2025. The company has also reappointed M/s. M. I. Prajapati & Associates as Cost Auditor for FY 2025-2026 with a remuneration of Rs. 55,000 plus taxes. Additional decisions include appointing a scrutinizer for e-voting and approving the 30th AGM notice and Directors' Report.
21Jul 25
Shree Ganesh Remedies Faces Rs. 88.61 Lacs GST Summons Over Expired Stock
Shree Ganesh Remedies Limited received a GST summons from the Superintendent of Central GST and Central Excise Unit, Vadodara, alleging violations related to expired stock in a company warehouse. The summons involves a potential GST liability of approximately Rs. 88.61 Lacs. The company, supported by legal and tax counsel, plans to contest the allegations, believing them to be untenable under existing law and judicial precedents. They intend to file an appeal before the appellate authority. The investigation is currently at a preliminary stage, and the company has informed BSE Limited about the summons in compliance with SEBI regulations.
19May 25
Shree Ganesh Remedies Reports Mixed Q4 Results with Profit Growth and Revenue Decline
Shree Ganesh Remedies' Q4 results show a mixed performance. Net profit increased to ₹66.00 crore from ₹54.00 crore in Q3, but decreased from ₹126.00 crore year-over-year. Revenue declined to ₹244.00 crore from ₹373.00 crore in the previous year. EBITDA fell to ₹9.90 crore from ₹16.90 crore, with EBITDA margin dropping to 40.44% from 45.40% year-over-year.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Zydus Life Science
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,799.20
(-2.45%)
6,667.00
(-1.92%)
4,410.80
(-2.80%)
1,401.00
(-1.21%)
1,303.50
(-1.18%)
1,077.70
(-0.75%)
2,267.70
(-0.38%)
2,375.60
(-1.85%)
1,426.40
(-0.66%)
1,362.00
(-1.43%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
